End Stage Renal Disease clinical trials at UCSF
4 in progress, 3 open to eligible people
End stage renal disease is when the kidneys stop working completely. UCSF is studying the impact of genetics on kidney transplant outcomes and donor safety. They are testing a drug for severe kidney disease in patients with a rare condition. UCSF is also exploring ways to manage blood pressure in those receiving dialysis.
DCR-PHXC in Patients With PH1 and ESRD
open to all eligible people
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
San Francisco, California and other locations
Home Blood Pressure (BP) Trial
open to eligible people ages 18 years and up
The main study will be a two arm 10-month, cross-over randomized controlled trial of 200 participants treated with end-stage-kidney-disease treated with in-center hemodialysis in the Seattle and San Francisco area comparing a strategy of targeting home vs. pre-dialysis systolic blood pressure <140 mmHg to reduce rates of intradialytic hypotension. The target systolic blood pressure of <140 mmHg in both treatment groups will be achieved using an algorithm of dry weight adjustment and anti-hypertensive medication adjustment.
San Francisco, California and other locations
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
open to all eligible people
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
San Francisco, California and other locations
Adding Urea to the Final Dialysis Fluid
Sorry, not yet accepting patients
At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations. These patients cannot be dialyzed aggressively as the lowering of serum BUN may results in disequilibrium syndrome but on the other hand they need aggressive dialysis in order to lower their serum potassium or fix their severe acidosis. If one is able to add urea to the dialysis fluid, one can prevent the rapid lowering of serum BUN and osmolality at the same time as doing aggressive dialysis to lower serum potassium and/or fix the metabolic acidosis.
San Francisco, California
Our lead scientists for End Stage Renal Disease research studies include Ramin Sam, MD Meyeon Park, MD Chi-yuan Hsu, MD.
Last updated: